In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria | Zendy

G J Malanoski | Zendy; L A Collins | Zendy; Christine Wennersten | Zendy; Robert C. Moellering | Zendy; George M. Eliopoulos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria

Author(s) -

G J Malanoski,

L A Collins,

Christine Wennersten,

Robert C. Moellering,

George M. Eliopoulos

Publication year - 1993

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.37.9.2009

Subject(s) - imipenem , bacteroides fragilis , microbiology and biotechnology , carbapenem , biology , gram negative bacteria , antimicrobial , thienamycin , bacteria , gram , antibacterial agent , in vitro , antibiotics , escherichia coli , antibiotic resistance , biochemistry , genetics , gene

The in vitro activity of biapenem, a new carbapenem previously designated L-627, was compared with those of imipenem and several other antimicrobial agents against 771 clinical bacterial isolates. Against gram-positive organisms, biapenem was found to be approximately as active as imipenem, inhibiting 90% of isolates of most species at concentrations within one dilution of the MIC of imipenem for 90% of the isolates. Against gram-negative organisms and Bacteroides fragilis, biapenem was at least as active as and often more active than imipenem, with MICs for 90% of the isolates two- to eightfold lower than those of imipenem.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research